Compare PMEC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | NRXP |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 151.1M |
| IPO Year | 2021 | 2017 |
| Metric | PMEC | NRXP |
|---|---|---|
| Price | $0.53 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 64.3K | ★ 615.5K |
| Earning Date | 07-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $1.65 |
| 52 Week High | $2.44 | $5.06 |
| Indicator | PMEC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 46.26 |
| Support Level | $0.31 | $3.09 |
| Resistance Level | $0.79 | $3.50 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 24.17 | 21.62 |
Primech Holdings Ltd is a cleaning business. The Company operates in two segments: commercial cleaning services and robotics. The Company is an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The Company generates revenue from services, which include services for general cleaning and maintenance of public and private facilities; cleaning of kitchen facilities of healthcare facilities, hotels and restaurants; and the supply of ad hoc customer; and cleaning services to offices.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.